TAIKO PHARMACEUTICAL CO., LTD. Logo

TAIKO PHARMACEUTICAL CO., LTD.

Manufactures OTC gastrointestinal medicine and leading infection control products.

4574 | T

Overview

Corporate Details

ISIN(s):
JP3442200006
LEI:
Country:
Japan
Address:
吹田市内本町三丁目34番14号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Taiko Pharmaceutical Co., Ltd. is a manufacturer and distributor specializing in pharmaceuticals and infection control products. The company operates through three primary business segments: Pharmaceutical, Infection Control, and Others. Its Pharmaceutical division is centered on its flagship product, Seirogan, an over-the-counter gastrointestinal medication with a history of over 100 years, used for treating symptoms like diarrhea and loose stools. The Infection Control division, a significant contributor to company revenue, develops and markets products including a leading brand of airborne disinfectants. The company is engaged in ongoing research and development to support its product lines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 08:35
Report Publication Announcement
確認書
Japanese 8.0 KB
2025-08-08 08:34
Interim Report
半期報告書-第80期(2025/01/01-2025/12/31)
Japanese 197.8 KB
2025-04-01 08:45
Post-Annual General Meeting Information
臨時報告書
Japanese 22.1 KB
2025-03-28 07:36
Regulatory News Service
臨時報告書
Japanese 19.1 KB
2025-03-28 07:35
Governance Information
内部統制報告書-第79期(2024/01/01-2024/12/31)
Japanese 22.1 KB
2025-03-28 07:33
Registration Form
確認書
Japanese 8.1 KB
2025-03-28 07:32
Annual Report
有価証券報告書-第79期(2024/01/01-2024/12/31)
Japanese 1011.8 KB
2024-08-09 08:34
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-08-09 08:33
Interim Report
半期報告書-第79期(2024/01/01-2024/12/31)
Japanese 210.9 KB
2024-05-10 08:37
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-05-10 08:35
Quarterly Report
四半期報告書-第79期第1四半期(2024/01/01-2024/03/31)
Japanese 164.9 KB
2024-04-01 08:14
Post-Annual General Meeting Information
臨時報告書
Japanese 23.7 KB
2024-03-28 07:30
Governance Information
内部統制報告書-第78期(2023/01/01-2023/12/31)
Japanese 22.1 KB
2024-03-28 07:28
Registration Form
確認書
Japanese 8.1 KB
2024-03-28 07:26
Annual Report
有価証券報告書-第78期(2023/01/01-2023/12/31)
Japanese 1.1 MB

Automate Your Workflow. Get a real-time feed of all TAIKO PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TAIKO PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TAIKO PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NuCana plc Logo
Develops safer anti-cancer medicines with ProTide technology to overcome cell resistance.
United States of America
NCNA
NUFORMIX PLC Logo
Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.
United Kingdom
NFX
Nurix Therapeutics, Inc. Logo
Developing protein degradation medicines to treat cancer and autoimmune diseases.
United States of America
NRIX
NUTEX Investments Plc Logo
Develops & distributes health, cosmetic & pharma products from natural ingredients globally.
Hungary
NUTEX
NutriBand Inc. Logo
Develops abuse-deterrent transdermal patches to make potent drug delivery safer.
United States of America
NTRB
Nuvalent, Inc. Logo
Designs targeted small molecule drugs for kinase-driven cancers to overcome treatment resistance.
United States of America
NUVL
Nuvation Bio Inc. Logo
A clinical-stage biopharma developing novel drugs for difficult-to-treat cancers.
United States of America
NUVB
Nxera Pharma Co., Ltd. Logo
Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.
Japan
4565
ObsEva SA Logo
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland
OBSN
OCULAR THERAPEUTIX, INC Logo
Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.
United States of America
OCUL

Talk to a Data Expert

Have a question? We'll get back to you promptly.